{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:40:27Z","timestamp":1767901227115,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18ek0109298"],"award-info":[{"award-number":["JP18ek0109298"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Progressive familial intrahepatic cholestasis (PFIC), a rare inherited disorder, progresses to liver failure in childhood. We have shown that sodium 4-phenylbutyrate (NaPB), a drug approved for urea cycle disorders (UCDs), has beneficial effects in PFIC. However, there is little evidence to determine an optimal regimen for NaPB therapy. Herein, a multicenter, open-label, single-dose study was performed to investigate the influence of meal timing on the pharmacokinetics of NaPB. NaPB (150\u2009mg\/kg) was administered orally 30\u2009min before, just before, and just after breakfast following overnight fasting. Seven pediatric PFIC patients were enrolled and six completed the study. Compared with postprandial administration, an approved regimen for UCDs, preprandial administration significantly increased the peak plasma concentration and area under the plasma concentration-time curve of 4-phenylbutyrate by 2.5-fold (95% confidential interval (CI), 2.0\u20133.0;P\u2009=\u20090.003) and 2.4-fold (95% CI, 1.7\u20133.2;P\u2009=\u20090.005). The observational study over 3 years in two PFIC patients showed that preprandial, but not prandial or postprandial, oral treatment with 500\u2009mg\/kg\/day NaPB improved liver function tests and clinical symptoms and suppressed the fibrosis progression. No adverse events were observed. Preprandial oral administration of NaPB was needed to maximize its potency in PFIC patients.<\/jats:p>","DOI":"10.1038\/s41598-019-53628-x","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T11:04:18Z","timestamp":1574161458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis"],"prefix":"10.1038","volume":"9","author":[{"given":"Satoshi","family":"Nakano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Osaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sabu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Minowa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeko","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2461-1303","authenticated-orcid":false,"given":"Hiroki","family":"Kondou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1878-1717","authenticated-orcid":false,"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayano","family":"Inui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Bessho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Tanikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Kage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Zen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-3454","authenticated-orcid":false,"given":"Mitsuyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-895X","authenticated-orcid":false,"given":"Hisamitsu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"key":"53628_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-4-1","volume":"4","author":"A Davit-Spraul","year":"2009","unstructured":"Davit-Spraul, A., Gonzales, E., Baussan, C. & Jacquemin, E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 4, 1, https:\/\/doi.org\/10.1186\/1750-1172-4-1 (2009).","journal-title":"Orphanet J Rare Dis"},{"key":"53628_CR2","doi-asserted-by":"publisher","unstructured":"Hayashi, H. et al. Assessment of ATP8B1 Deficiency in Pediatric Patients With Cholestasis Using Peripheral Blood Monocyte-Derived Macrophages. EBioMedicine, https:\/\/doi.org\/10.1016\/j.ebiom.2017.10.007 (2017).","DOI":"10.1016\/j.ebiom.2017.10.007"},{"key":"53628_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/ng0398-219","volume":"18","author":"LN Bull","year":"1998","unstructured":"Bull, L. N. et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 18, 219\u2013224, https:\/\/doi.org\/10.1038\/ng0398-219 (1998).","journal-title":"Nat Genet"},{"key":"53628_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10713","volume":"7","author":"N Gomez-Ospina","year":"2016","unstructured":"Gomez-Ospina, N. et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun 7, 10713, https:\/\/doi.org\/10.1038\/ncomms10713 (2016).","journal-title":"Nat Commun"},{"key":"53628_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/ng.2918","volume":"46","author":"M Sambrotta","year":"2014","unstructured":"Sambrotta, M. et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet 46, 326\u2013328, https:\/\/doi.org\/10.1038\/ng.2918 (2014).","journal-title":"Nat Genet"},{"key":"53628_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/3034","volume":"20","author":"SS Strautnieks","year":"1998","unstructured":"Strautnieks, S. S. et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 20, 233\u2013238, https:\/\/doi.org\/10.1038\/3034 (1998).","journal-title":"Nat Genet"},{"key":"53628_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0031-1272831","volume":"31","author":"RA Morotti","year":"2011","unstructured":"Morotti, R. A., Suchy, F. J. & Magid, M. S. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings. Semin Liver Dis 31, 3\u201310, https:\/\/doi.org\/10.1055\/s-0031-1272831 (2011).","journal-title":"Semin Liver Dis"},{"key":"53628_CR8","doi-asserted-by":"publisher","unstructured":"Suchy, F. J., Sundaram, S. & Shneider, B. 13. Familial Hepatocellular Cholestasis. Liver Disease in Children, 4th Edition, 199\u2013215, https:\/\/doi.org\/10.1017\/Cbo9780511547409.001 (2014).","DOI":"10.1017\/Cbo9780511547409.001"},{"key":"53628_CR9","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1399-0012.2010.01368.x","volume":"25","author":"T Hori","year":"2011","unstructured":"Hori, T. et al. Progressive familial intrahepatic cholestasis: a single-center experience of living-donor liver transplantation during two decades in Japan. Clin Transplant 25, 776\u2013785, https:\/\/doi.org\/10.1111\/j.1399-0012.2010.01368.x (2011).","journal-title":"Clin Transplant"},{"key":"53628_CR10","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa0901075","volume":"361","author":"P Jara","year":"2009","unstructured":"Jara, P. et al. Recurrence of bile salt export pump deficiency after liver transplantation. N Engl J Med 361, 1359\u20131367, https:\/\/doi.org\/10.1056\/NEJMoa0901075 (2009).","journal-title":"N Engl J Med"},{"key":"53628_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/hep.23083","volume":"50","author":"V Keitel","year":"2009","unstructured":"Keitel, V. et al. De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis. Hepatology 50, 510\u2013517, https:\/\/doi.org\/10.1002\/hep.23083 (2009).","journal-title":"Hepatology"},{"key":"53628_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jhep.2010.05.025","volume":"53","author":"G Maggiore","year":"2010","unstructured":"Maggiore, G. et al. Relapsing features of bile salt export pump deficiency after liver transplantation in two patients with progressive familial intrahepatic cholestasis type 2. J Hepatol 53, 981\u2013986, https:\/\/doi.org\/10.1016\/j.jhep.2010.05.025 (2010).","journal-title":"J Hepatol"},{"key":"53628_CR13","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1002\/hep.25591","volume":"55","author":"H Hayashi","year":"2012","unstructured":"Hayashi, H. et al. AP2 adaptor complex mediates bile salt export pump internalization and modulates its hepatocanalicular expression and transport function. Hepatology 55, 1889\u20131900 (2012).","journal-title":"Hepatology"},{"key":"53628_CR14","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/hep.21630","volume":"45","author":"H Hayashi","year":"2007","unstructured":"Hayashi, H. & Sugiyama, Y. 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology 45, 1506\u20131516 (2007).","journal-title":"Hepatology"},{"key":"53628_CR15","doi-asserted-by":"publisher","first-page":"C1709","DOI":"10.1152\/ajpcell.00327.2007","volume":"293","author":"P Lam","year":"2007","unstructured":"Lam, P. et al. Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep\/Abcb11) correlate with severity of cholestatic diseases. Am J Physiol Cell Physiol 293, C1709\u20131716, https:\/\/doi.org\/10.1152\/ajpcell.00327.2007 (2007).","journal-title":"Am J Physiol Cell Physiol"},{"key":"53628_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jhep.2012.04.017","volume":"57","author":"E Gonzales","year":"2012","unstructured":"Gonzales, E. et al. Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2. J Hepatol 57, 695\u2013698, https:\/\/doi.org\/10.1016\/j.jhep.2012.04.017 (2012).","journal-title":"J Hepatol"},{"key":"53628_CR17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/hep.27767","volume":"62","author":"E Gonzales","year":"2015","unstructured":"Gonzales, E. et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology 62, 558\u2013566, https:\/\/doi.org\/10.1002\/hep.27767 (2015).","journal-title":"Hepatology"},{"key":"53628_CR18","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/hep.20627","volume":"41","author":"H Hayashi","year":"2005","unstructured":"Hayashi, H., Takada, T., Suzuki, H., Akita, H. & Sugiyama, Y. Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP\/ABCB11. Hepatology 41, 916\u2013924 (2005).","journal-title":"Hepatology"},{"key":"53628_CR19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.jpeds.2013.12.032","volume":"164","author":"S Naoi","year":"2014","unstructured":"Naoi, S. et al. Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2. J Pediatr 164, 1219\u20131227 e1213, https:\/\/doi.org\/10.1016\/j.jpeds.2013.12.032 (2014).","journal-title":"J Pediatr"},{"key":"53628_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-89","volume":"9","author":"Y Hasegawa","year":"2014","unstructured":"Hasegawa, Y. et al. Intractable itch relieved by 4-phenylbutyrate therapy in patients with progressive familial intrahepatic cholestasis type 1. Orphanet J Rare Dis 9, 89, https:\/\/doi.org\/10.1186\/1750-1172-9-89 (2014).","journal-title":"Orphanet J Rare Dis"},{"key":"53628_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1053\/j.gastro.2003.12.013","volume":"126","author":"F Chen","year":"2004","unstructured":"Chen, F. et al. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 126, 756\u2013764 (2004).","journal-title":"Gastroenterology"},{"key":"53628_CR22","doi-asserted-by":"publisher","first-page":"9947","DOI":"10.1074\/jbc.M808667200","volume":"284","author":"CC Paulusma","year":"2009","unstructured":"Paulusma, C. C., de Waart, D. R., Kunne, C., Mok, K. S. & Elferink, R. P. Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content. J Biol Chem 284, 9947\u20139954, https:\/\/doi.org\/10.1074\/jbc.M808667200 (2009).","journal-title":"J Biol Chem"},{"key":"53628_CR23","doi-asserted-by":"publisher","unstructured":"Malatack, J. J. & Doyle, D. A Drug Regimen for Progressive Familial Cholestasis Type 2. Pediatrics, 141, https:\/\/doi.org\/10.1542\/peds.2016-3877 (2018).","DOI":"10.1542\/peds.2016-3877"},{"key":"53628_CR24","unstructured":"(FDA), U. F. a. D. A. Labels for NDA 020572: BUPHENYL\u00ae (sodium phenylbutyrate) (2009)."},{"key":"53628_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s10038-018-0431-1","volume":"63","author":"K Imagawa","year":"2018","unstructured":"Imagawa, K. et al. Clinical phenotype and molecular analysis of a homozygous ABCB11 mutation responsible for progressive infantile cholestasis. J Hum Genet 63, 569\u2013577, https:\/\/doi.org\/10.1038\/s10038-018-0431-1 (2018).","journal-title":"J Hum Genet"},{"key":"53628_CR26","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/hep.23589","volume":"51","author":"BM McGuire","year":"2010","unstructured":"McGuire, B. M. et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 51, 2077\u20132085, https:\/\/doi.org\/10.1002\/hep.23589 (2010).","journal-title":"Hepatology"},{"key":"53628_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jpeds.2004.10.047","volume":"146","author":"H Nagasaka","year":"2005","unstructured":"Nagasaka, H. et al. Evaluation of risk for atherosclerosis in Alagille syndrome and progressive familial intrahepatic cholestasis: two congenital cholestatic diseases with different lipoprotein metabolisms. J Pediatr 146, 329\u2013335, https:\/\/doi.org\/10.1016\/j.jpeds.2004.10.047 (2005).","journal-title":"J Pediatr"},{"key":"53628_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/MPG.0000000000001082","volume":"62","author":"BL Shneider","year":"2016","unstructured":"Shneider, B. L., Morris, A. & Vockley, J. Possible Phenylacetate Hepatotoxicity During 4-Phenylbutyrate Therapy of Byler Disease. J Pediatr Gastroenterol Nutr 62, 424\u2013428, https:\/\/doi.org\/10.1097\/MPG.0000000000001082 (2016).","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"53628_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ymgmr.2016.07.003","volume":"8","author":"OA Shchelochkov","year":"2016","unstructured":"Shchelochkov, O. A. et al. Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives. Mol Genet Metab Rep 8, 43\u201347, https:\/\/doi.org\/10.1016\/j.ymgmr.2016.07.003 (2016).","journal-title":"Mol Genet Metab Rep"},{"key":"53628_CR30","first-page":"2292","volume":"7","author":"J Gilbert","year":"2001","unstructured":"Gilbert, J. et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7, 2292\u20132300 (2001).","journal-title":"Clin Cancer Res"},{"key":"53628_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jpeds.2016.01.006","volume":"171","author":"T Togawa","year":"2016","unstructured":"Togawa, T. et al. Molecular Genetic Dissection and Neonatal\/Infantile Intrahepatic Cholestasis Using Targeted Next-Generation Sequencing. J Pediatr 171, 171\u2013177 e174, https:\/\/doi.org\/10.1016\/j.jpeds.2016.01.006 (2016).","journal-title":"J Pediatr"},{"key":"53628_CR32","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/gut.50.3.436","volume":"50","author":"MI Prince","year":"2002","unstructured":"Prince, M. I., Burt, A. D. & Jones, D. E. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 50, 436\u2013439 (2002).","journal-title":"Gut"},{"key":"53628_CR33","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0140-6736(74)92381-2","volume":"1","author":"PJ Scheuer","year":"1974","unstructured":"Scheuer, P. J., Summerfield, J. A., Lal, S. & Sherlock, S. Rifampicin hepatitis. A clinical and histological study. Lancet 1, 421\u2013425 (1974).","journal-title":"Lancet"},{"key":"53628_CR34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jhep.2009.11.012","volume":"52","author":"JM Stapelbroek","year":"2010","unstructured":"Stapelbroek, J. M., van Erpecum, K. J., Klomp, L. W. & Houwen, R. H. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol 52, 258\u2013271, https:\/\/doi.org\/10.1016\/j.jhep.2009.11.012 (2010).","journal-title":"J Hepatol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53628-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:12:46Z","timestamp":1671293566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53628-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["53628"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53628-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"assertion":[{"value":"12 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Hiroki Kondou has received NaPB for free from OrphanPacific, Inc. for an ongoing clinical trial (UMIN000024753). The other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17075"}}